Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $9.43 in the last session, up 1.84% from day before closing price of $9.26. In other words, the price has increased by $1.84 from its previous closing price. On the day, 1.96 million shares were traded. ARQT stock price reached its highest trading level at $9.46 during the session, while it also had its lowest trading level at $8.98.
Ratios:
We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.46. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 0.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On January 03, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $8.
Mizuho Downgraded its Buy to Neutral on October 26, 2023, whereas the target price for the stock was revised from $57 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 14 ’24 when Burnett Patrick sold 69,126 shares for $10.29 per share. The transaction valued at 711,618 led to the insider holds 128,669 shares of the business.
Burnett Patrick sold 100 shares of ARQT for $1,003 on Nov 15 ’24. The insider now owns 128,669 shares after completing the transaction at $10.03 per share. On Nov 15 ’24, another insider, Burnett Patrick, who serves as the Officer of the company, bought 100 shares for $10.03 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1103734400 and an Enterprise Value of 981347520. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.42 while its Price-to-Book (P/B) ratio in mrq is 7.04. Its current Enterprise Value per Revenue stands at 7.075 whereas that against EBITDA is -5.47.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -1.74%, while the 200-Day Moving Average is calculated to be 0.03%.
Shares Statistics:
According to the various share statistics, ARQT traded on average about 2.05M shares per day over the past 3-months and 3005020 shares per day over the past 10 days. A total of 117.05M shares are outstanding, with a floating share count of 102.89M. Insiders hold about 12.09% of the company’s shares, while institutions hold 102.99% stake in the company. Shares short for ARQT as of 1730332800 were 27755696 with a Short Ratio of 13.53, compared to 1727654400 on 27129867. Therefore, it implies a Short% of Shares Outstanding of 27755696 and a Short% of Float of 29.349999999999998.
